


Amendments to the Claims:Listing of Claims:

Claim 1 (currently amended): ~~Use A method comprising~~ of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide of formula



or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a mutated-RET kinase associated disease.

Claim 2 (currently amended): The ~~use method~~ of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide or a pharmaceutically acceptable salt thereof in the treatment of a mutated-RET kinase associated disease.

Claim 3 (currently amended): The ~~use method~~ according to claim 1 ~~or 2~~ wherein the mutated-RET kinase associated diseases comprises thyroid cancers, pheochromocytoma, mucosal neuromas, hyperparathyroidism, parathyroid hyperplasia, Hirschsprungs disease or Cutaneous Lichen amyloidosis.

Claim 4 (currently amended): The ~~use method~~ according to ~~any one of claims 1 to 3~~ claim 1 wherein the thyroid cancer is selected from medullary thyroid carcinomas and papillary thyroid carcinomas.

Claim 5 (currently amended): The ~~use method~~ according to claim 4 wherein the medullary thyroid carcinomas are the hereditary multiple endocrine neoplasias type 2.

Claim 6 (currently amended): The ~~use method~~ according to claim 5 wherein the hereditary multiple endocrine neoplasias type 2 are MEN2A, MEN2B or FMTC.

Claim 7 (original): A method of treating warm-blooded animals including humans suffering from a mutated-RET kinase associated disease which comprises administering to a said warm-blooded animal in need of such a treatment a dose, effective against said disease, of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide or a pharmaceutically acceptable salt thereof.

Claim 8 (original): A method according to claim 7 wherein a daily dose of 10 to 1000 mg of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of formula I is administered to an adult.

Claim 9 (original): A method according to claim 8 wherein the monomethanesulfonate salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide is administered.

Claim 10 (currently amended): ~~Use or method~~Method according to ~~any of the preceding claims-claim 1~~ wherein 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide is in mesylate salt form and in the beta crystal form thereof.